



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 62034

**Title:** Prognostic role of sarcopenia in metastatic colorectal cancer patients during first line chemotherapy: A retrospective study

**Reviewer's code:** 05116713

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2020-12-26

**Reviewer chosen by:** Jin-Lei Wang

**Reviewer accepted review:** 2020-12-28 09:26

**Reviewer performed review:** 2020-12-28 09:32

**Review time:** 1 Hour

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Although the result of the study was negative, that's fine, as that answers the question asked, within the scope of the limited sample size (a factor that the authors state). Statistical analyses and interpretations seem adequate and the paper is also adequately written. As such, it is acceptable, and represents a contribution to the field.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 62034

**Title:** Prognostic role of sarcopenia in metastatic colorectal cancer patients during first line chemotherapy: A retrospective study

**Reviewer's code:** 01588319

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2020-12-26

**Reviewer chosen by:** Jin-Lei Wang

**Reviewer accepted review:** 2020-12-28 03:24

**Reviewer performed review:** 2021-01-19 00:14

**Review time:** 21 Days and 20 Hours

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

#### **SPECIFIC COMMENTS TO AUTHORS**

1. The definition of sarcopenia is only based on SMI in this study. It is different from the current guideline for defining sarcopenia (for European or Asian population), please clarify it. 2. There were 14 patients with sarcopenia at the baseline, the authors also reported that 7 patients became sarcopenic. Why this study did not analyze these 7 patients with sarcopenia? 3. Although this study focused on mCRC, the authors reported that 23 patients had II or III stage disease according to the pTNM classification and they subsequently developed metastases; 33 patients received the diagnosis at metastatic stage. This implied that 56 so-called "mCRC" patients with different time points of metastasis which will lead to different clinical outcomes, please clarify it. 4. The contents of the "Discussion" section should be concise. For example, the relevant descriptions of the study conducted by Prado et al. are too much. Please avoid describing the detail contents and just focus on discussing the key points. 5. In Table 1, the p values for the "Toxicity during the first 4 chemotherapy cycles" should not be "1", please provide the true p values.